[
    [
        {
            "time": "2021-04-16",
            "original_text": "【中银医药】凯莱英：兼顾“做深”与“做广”，业绩实现稳定增长",
            "features": {
                "keywords": [
                    "凯莱英",
                    "业绩",
                    "稳定增长",
                    "做深",
                    "做广"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【中银医药】凯莱英：兼顾“做深”与“做广”，业绩实现稳定增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "西南证券 - 凯莱英：业绩符合预期，Q4增长显着提速【公司研究】",
            "features": {
                "keywords": [
                    "凯莱英",
                    "业绩",
                    "Q4",
                    "增长提速"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券 - 凯莱英：业绩符合预期，Q4增长显着提速【公司研究】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "东莞证券 - 凯莱英2020年年报点评：项目数量持续高增，国内市场加速发力【公司研究】",
            "features": {
                "keywords": [
                    "凯莱英",
                    "2020年报",
                    "项目数量",
                    "国内市场",
                    "加速发力"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东莞证券 - 凯莱英2020年年报点评：项目数量持续高增，国内市场加速发力【公司研究】",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "东吴证券 - 凯莱英2020年年报点评：业绩符合我们预期，小分子CDMO龙头发展有望提速【公司研究】",
            "features": {
                "keywords": [
                    "凯莱英",
                    "2020年报",
                    "小分子CDMO",
                    "龙头",
                    "发展提速"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券 - 凯莱英2020年年报点评：业绩符合我们预期，小分子CDMO龙头发展有望提速【公司研究】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "国盛证券 - 凯莱英：2020圆满收官，biotech和国内持续发力，5大新业务板块推进【公司研究】",
            "features": {
                "keywords": [
                    "凯莱英",
                    "2020",
                    "biotech",
                    "国内",
                    "新业务板块"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券 - 凯莱英：2020圆满收官，biotech和国内持续发力，5大新业务板块推进【公司研究】",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "年报解读|凯莱英创下单季度营收历史新高加快布局大分子CDMO等战略性业务",
            "features": {
                "keywords": [
                    "凯莱英",
                    "单季度营收",
                    "历史新高",
                    "大分子CDMO",
                    "战略布局"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "年报解读|凯莱英创下单季度营收历史新高加快布局大分子CDMO等战略性业务",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-04-16",
            "original_text": "国金证券 - 凯莱英：项目管线持续丰富，综合服务能力持续提升【公司研究】",
            "features": {
                "keywords": [
                    "凯莱英",
                    "项目管线",
                    "综合服务能力",
                    "提升"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券 - 凯莱英：项目管线持续丰富，综合服务能力持续提升【公司研究】",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]